Articles tagged with Pancreatic Cancer
Researchers have discovered a novel role for CD40 antibodies in re-educating macrophages to break down the tumor microenvironment, allowing chemotherapy to target pancreatic cancer more effectively. The optimal timing of delivery is critical, with chemotherapy being most effective when administered five days after CD40 treatment.
Researchers develop integrase-defective lentiviral vector to deliver chemotherapy-sensitizing gene to pancreatic tumor cells, reducing risk of insertional mutagenesis. The system enables high efficacy delivery of the gene that encodes for DCK protein to cancer cells, making them more sensitive to chemotherapeutic drug gemcitabine.
Research breakthrough reveals pancreatic tumours often lose miR-137 expression, triggering uncontrolled cell growth and cancer. Restoring normal miR-137 levels induces senescence and stops cells from spreading.
A new study reveals that pancreatic cancer is composed of four distinct subtypes, each with its own unique genetic profile and treatment possibilities. These findings have significant implications for diagnosis and treatment, potentially allowing for more accurate prognoses and targeted therapies.
A new study suggests that patients with resectable pancreatic cancer should receive at least 6 months of adjuvant chemotherapy to reduce distant disease recurrences and improve overall survival. Chemotherapy, but not chemoradiotherapy, significantly reduces the incidence of distant recurrence.
A new study by Texas Tech University Health Sciences Center El Paso found that a compound in neem leaves can stop pancreatic cancer growth and metastasis without harming normal cells. The researchers observed a 70% reduction in cancer cell migration and invasion, as well as an 80% drop in cancer cell colonies.
The charity has funded 40 research projects worth over £6 million, including grants for innovative treatments and personalised medicine approaches. Six new projects aim to develop imaging techniques, epigenetic biomarkers, and targeted therapies to improve patient outcomes.
Researchers at UT Southwestern Medical Center have discovered that CDK4/6 inhibitors alter the metabolism of pancreatic cancer cells, revealing a biologic vulnerability. By targeting altered tumor metabolism with other drugs, it may be possible to positively impact cancer treatment.
The UK's first national tissue bank aims to develop new treatments and improve patient outcomes for pancreatic cancer. The Tissue Bank will store high-quality samples from consenting patients, enabling researchers to test ideas and validate their research more effectively.
Researchers found that metformin decreases inflammation and fibrosis in pancreatic cancer, which may be most prevalent in overweight and obese patients. The study also identified a potential biomarker for response to metformin treatment based on patient body weight.
A study published in the British Journal of Cancer found that higher magnesium intake may lower the risk of pancreatic cancer. Researchers analyzed data from over 66,000 men and women and discovered a significant association between magnesium consumption and reduced pancreatic cancer incidence.
Researchers at MD Anderson Cancer Center have developed a new liquid biopsy technique that can analyze tumor genes from blood samples using exosomes, providing a non-invasive alternative to traditional biopsies. The approach has the potential to improve prognosis, guide targeted therapy, and monitor treatment progress.
Researchers found CTCs in 100% of patients with suspected tumors, but only 4% detected through peripheral blood. Portal vein samples provided more accurate tumor cell information, enabling better clinical decisions. The test could help predict patient outcomes and guide treatment options.
A study found that socioeconomic factors like race, ethnicity, insurance status, and geographic location affect the likelihood of undergoing surgery for early-stage pancreatic cancer. Patients who underwent resection had improved disease-specific survival compared to those who did not, with regional differences in survival rates observed.
A new study developed a potential test to sort out precancerous pancreatic cysts from harmless ones, with an accuracy rate of up to 98 percent. The test combines genetic markers and clinical evaluation, potentially helping patients avoid unnecessary surgery.
Researchers at IUPUI developed a nanotech-based sensor to detect microRNAs in blood, enabling early cancer diagnosis and potentially improving treatment outcomes. The sensor's ultrasensitivity allows for the detection of minute changes in microRNA concentrations.
Researchers discovered peptides that inhibit metastatic spreading and even lead to regression of existing metastases in pancreatic cancer models. The CD44v6 protein drives the spread of tumor cells, but small segments of the protein can be successfully inhibited by peptides.
Researchers are developing new technologies to analyze pancreatic tumor super-enhancers and testing therapies targeting these signals in clinical trials. The goal is to reprogram cancer cells or create vulnerabilities that can be exploited with combination drug therapies.
A team of top researchers, led by TGen's Dr. Daniel D. Von Hoff, aims to develop therapies that greatly improve patient survival. They will focus on reprogramming the 'super enhancers' in cancer cells to stop tumor growth and offer novel treatments for patients with pancreatic cancer.
A team of top researchers will focus on reprogramming pancreatic tumor biology using cutting-edge technology and developing new SE-targeted drugs. The goal is to dial up sensitivity to chemotherapy and push tumors into lasting remission.
A recent study by Mayo Clinic reveals that only one in five US pancreatic cancer patients receive the CA 19-9 tumor marker test at diagnosis, which can help predict treatment outcomes and guide personalized treatment. The test eliminates negative effects on survival when chemotherapy is administered before surgery.
Researchers have discovered a genomic molecular fingerprint, signature 3, that highlights certain gastric cancers susceptible to treatment with platinum drugs or PARP inhibitor drugs. This biomarker could guide targeted therapy for breast, ovarian and pancreatic cancers as well.
A new study by Fred Hutchinson Cancer Center researchers found that immunotherapy can boost survival from pancreatic cancer by more than 75% in mice, even without chemotherapy or radiation. The therapy targets mesothelin, a protein overproduced by virtually all pancreatic tumors.
New data from clinical trials at Penn Medicine demonstrate the clinical benefits of proton therapy for patients with advanced lung, pancreatic, and spine cancers. Proton therapy has been shown to reduce toxicities and improve survival rates compared to conventional radiation therapy.
UT Southwestern researchers have developed a classification model for cancers caused by KRAS, the most frequently mutated gene in cancer. The model helps predict the propensity of different KRAS mutants to signal through RAF kinase and could lead to more effective targeted therapies.
A Binghamton University biochemist has discovered a method to fight cancer by attacking only cancer cells and potentially reducing side effects. Hedgehogs, which normally turn off in mature cells, somehow re-activate in certain cancers, leading to uncontrolled cell growth.
Researchers have found that a protein called FAK plays a key role in the development of pancreatic neuroendocrine tumors. A two-drug combination has been shown to be more effective than everolimus alone in killing cancer cells and reducing tumor volume.
A combination of two drugs has been found to shrink pancreatic tumors in laboratory mice. The treatment, which targets the cell's DNA rather than proteins, also slowed the growth of human lung cancer cells. Researchers are now working to test this treatment in humans with pancreatic cancer.
A five-year programme will focus on developing miniscule technology to deliver drugs directly to cancer sites, improving chemotherapy effectiveness. The project tackles an important area around drug delivery in pancreatic cancer, which is the fifth most common cause of cancer deaths in the UK.
Researchers have discovered that an anti-diabetic drug can 'suffocate' pancreatic cancer stem cells by preventing them from using oxygen for energy. This finding holds promise for developing new treatments that target these cancer stem cells and prevent recurrence after conventional treatment. Pancreatic cancer remains one of the most ...
Researchers at H. Lee Moffitt Cancer Center are developing a blood test using microRNAs to identify and characterize precursor lesions that can progress to pancreatic cancer. The test may help differentiate between low- and high-risk lesions, allowing for more informed personalized medical management decisions.
University of Houston researchers identify liver X receptors as a promising target for developing new pancreatic cancer treatments. The study, led by Chin-Yo Lin, shows that targeting these receptors can slow the growth of tumors and is expected to lead to the development of new drugs.
A study found genes associated with improved survival after surgery for pancreatic cancer patients. Detection of circulating tumor DNA in the blood predicted clinical relapse and poor outcomes.
Scientists at Johns Hopkins Medicine identified a molecular partnership between annexin A2 and Sema3D that helps explain how pancreatic cancer spreads. Annexin A2, already linked to poor survival rates, guides the release of Sema3D, which fuels the cancer's spread by tracking nerve cells.
Researchers at Barts Cancer Institute have identified a three-protein 'signature' in urine that can accurately detect early-stage pancreatic cancer with over 90% accuracy. This discovery could lead to a simple and inexpensive test for high-risk individuals, improving survival rates.
Researchers found no statistically significant association between pioglitazone use and bladder cancer risk. However, a small increased risk was observed, as well as associations with increased prostate and pancreatic cancer risks.
A recent genome-sequencing study discovered at least one-third of patients' tumors have genetic mutations that can guide precision therapy. Blood tests detecting DNA shed from tumors predicted cancer recurrence more than half a year earlier than standard imaging methods.
Scientists at University College London have designed a chemical compound called MM41 that targets quadruplexes, faulty genes found in pancreatic cancers. The compound reduced tumor growth by 80% and prevented regrowth in mice, showing promise for treating pancreatic cancer.
Indiana University researchers found that restoring missing microRNA-29 in pancreatic cancer stromal cells reduced the viability and growth of cancerous cells. The study suggests that miR-29 could be a potent therapeutic agent against pancreatic cancer by targeting reactive tumor stroma.
Researchers at MD Anderson Cancer Center have identified a potential non-invasive diagnostic tool for early pancreatic cancer detection. Glypican-1-enriched circulating exosomes were found to be present in small amounts of serum from patients with pancreatic cancer, showing high specificity and sensitivity. Early detection of pancreati...
Researchers have uncovered four regions in the human genome where changes may increase pancreatic cancer risk, with specific variants linked to a 38% increased risk at position 17q25.1. The study confirms connections between pancreatic cancer risk and genetic variants linked to other cancers.
Leading researchers from Canada and Israel are working together to uncover the molecular landscape of pancreatic cancer and develop new biomarkers for detection and diagnostics. The collaboration aims to improve patient outcomes by discovering targeted therapies.
A systematic review and meta-analysis of 36 observational studies found that nut consumption is associated with a decreased risk of colorectal cancer, endometrial cancer, and pancreatic cancer. However, it was not linked to type 2 diabetes.
Researchers at VCU Massey Cancer Center have found a promising combination of an experimental drug and common antibiotic Minocycline to target pancreatic cancer cells. The synergistic effect of the two drugs eliminated Stat3 expression, a key protein regulating tumor growth.
A study published in Nature Cell Biology reveals that exosomes secreted by pancreatic cancer cells contain MIF, which educates liver cells to produce a protein leading to fibrosis and tumor growth. This discovery could lead to targeted treatments and biomarkers for early detection.
Researchers found that stereotactic body radiation therapy (SBRT) is safe and as effective as standard radiation treatment for certain patients with locally advanced pancreatic cancer. SBRT delivers high doses of radiation in a short period, resulting in reduced pain and improved quality of life. The treatment also allowed some patient...
Researchers at UC San Diego found that pancreatic cancer rates are highest in countries with the least amount of sunlight, due to low vitamin D levels. Limited foods naturally contain vitamin D, and experts suggest that a deficiency may contribute to an increased risk of pancreatic cancer.
Despite recent advances in understanding pancreatic cancer biology, researchers have made little progress in finding effective treatments. However, a new review suggests that immunotherapy combined with other treatments may significantly increase patient survival rates, and could lead to new therapeutic strategies.
Researchers identify ways to improve recruitment and efficiency of IMPaCT trial, a personalized pancreas cancer clinical trial that used genomic sequencing to guide treatment. The trial showed promise despite initial challenges, including slow technology adoption and complex administrative processes.
DECT imaging enhances pancreatic cancer assessment through improved lesion detection and characterization, potentially improving patient outcomes. The technique has shown promise in detecting and evaluating pancreatic tumors, offering a more comprehensive analysis than traditional single-energy CT imaging.
Researchers have identified a novel approach to treating pancreatic cancer by introducing the protein E47, which can reprogram cancer cells back to their original state. This breakthrough offers new therapeutic possibilities and may lead to improved patient outcomes.
Researchers have discovered a way to make pancreatic cancer cells more susceptible to oncolytic viruses by exploiting the communication between cancer cells and supportive cells, such as cancer-associated fibroblasts. This weakness can be exploited to improve treatment outcomes for patients with pancreatic cancer.
The American Association for Cancer Research (AACR) and Pancreatic Cancer Action Network have awarded $27 million in research grants to support innovative projects targeting pancreatic cancer. The grants aim to improve treatment and diagnosis of the deadly disease, which has the lowest survival rate among major cancers.
Researchers at Mayo Clinic have developed a profile to identify patients most at risk of developing pancreatic cancer. The study analyzed data from 1,126 patients and found that factors such as history of smoking, obesity, jaundice, and cyst size on imaging scans are associated with high risk.
Researchers at UT Southwestern Medical Center have identified a wealth of genetic diversity in pancreatic cancer, including multiple mutated genes that were previously unknown. The study also revealed potential diagnostic biomarkers and defined cases where certain drugs are selectively effective against specific mutations.
A magnetic resonance imaging (MRI)-based screening program identified pancreatic lesions in 40% of high-risk patients, with 5 requiring surgery. The study suggests that MRI can detect cancer or premalignant lesions with good accuracy, reducing costs and increasing availability compared to more aggressive methods.
Researchers at TGen are using zebrafish to accelerate investigations of pancreatic cancer, with the goal of finding therapeutics that can slow down and reverse tumor growth. The study is funded by the Seena Magowitz Foundation and aims to understand how pancreatic cancer invades local tissue and spreads to other organs.
Many cancers, including pancreatic cancer, enslave and deform mitochondria to create an environment conducive to tumor growth. Researchers found that blocking this process may lead to the growth of tumors.
Dr. Elizabeth Jaffee receives the AACR-Joseph H. Burchenal Award for her pioneering contributions to immunotherapies for breast and pancreatic cancers, leading to improved treatments and patient outcomes. Her work also focuses on establishing biomarkers of tumor microenvironment reprogramming.
Scientists at UTHealth received grants to identify new compounds that may treat lethal cancers by targeting K-Ras protein mutations. The research aims to develop anti-KRas drugs to improve treatment outcomes for millions suffering from these cancers.